secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001628280-23-026568
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx Q2 2023: IBSRELA rev $18.3M (+61% QoQ), net loss $17.1M, FY23 guidance $72-77M
--------------------------------------------------------------------------------

- IBSRELA net sales $18.3M in Q2 2023, up 61% QoQ from $11.4M in Q1.
- Total revenues $22.3M (incl $4.0M licensing); net loss $17.1M ($0.08/sh) narrowed from $26.9M loss in Q2 2022.
- FY2023 IBSRELA net sales guided to $72-77M; management sees $500M+ peak sales potential.
- XPHOZAH NDA under FDA review (PDUFA Oct 17, 2023); launch prep underway for Q4 2023 pending approval.
- Cash $127.6M at June 30, 2023; raised $11.6M via ATM in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023026568/0001628280-23-026568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023026568/ardx-20230802.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-026568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer